Cover 17

Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Ltgehetmann M, Bertoletti A, Dandri M.J Clin Invest. 2017 Aug 1;127(8):3177-3188. doi: 10.1172/JCI93024.

Cover 17

Tolerance and immunity to pathogens in early life: insights from HBV infection.

Hong M, Bertoletti A.SeminImmunopathol. 2017 Jul 6. doi: 10.1007/s00281-017-0641-1.

Cover 03

E3 Ubiquitin ligase ZNRF4 negatively regulates NOD2 signalling and induces tolerance to MDP.

Bist P, Cheong WS, Ng A, Dikshit N, Kim BH, Pulloor NK, Khameneh HJ, Hedl M, Shenoy AR, Balamuralidhar V, Malik NBA, Hong M, Neutzner A, Chin KC, Kobayashi KS, Bertoletti A, Mortellaro A, Abraham C, MacMicking JD, Xavier RJ, Sukumaran B.Nat Commun. 2017 Jun 28;8:15865. doi: 10.1038/ncomms15865.

Cover 04

A 3Dmicrofluidicmodel for preclinicalevaluation of TCR-engineered T cells against solid tumors.

Pavesi A, Tan AT, Koh S, Chia A, Colombo M, Antonecchia E, Miccolis C, Ceccarello E, Adriani G, Raimondi MT, Kamm RD, Bertoletti A. JCI Insight. 2017 Jun 15;2(12). pii: 89762. doi: 10.1172/jci.insight.89762.

Cover 05

Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus.

Gill US, Bertoletti A.Semin Liver Dis. 2017 May;37(2):85-94. doi: 10.1055/s-0037-1600522. Epub 2017 May 31.

Cover 06

IntrahepaticCD206+ macrophagescontribute to inflammation in advancedviral-relatedliverdisease.

Tan-GarciaA, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, Khakpoor A, Chia A, Tham C, Tan A, Hong M, Keng C T, Rivino L, Tan K C5, Lee K H, Lim S G, Newell E, Pavelka N, Chen J, Ginhoux F, Chen Q , Bertoletti A and Dutertre C. J Hepatol. 2017 May 5. pii: S0168-8278(17)32004-4. doi: 10.1016/j.jhep.2017.04.023.

Cover 07

Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.

Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Viruses. 2017 Apr 29;9(5). pii: E96. doi: 10.3390/v9050096. Review

Cover 08

Corrigendum: CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.

Yeap WH, Wong KL, Shimasaki N, Teo EC, Quek JK, Yong HX, Diong CP, Bertoletti A, Linn YC, Wong SC.Sci Rep. 2017 Apr 7;7:46202. doi: 10.1038/srep46202.

Cover 09

Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties.

Balasiddaiah A, Davanian H, Aleman S, Pasetto A, Frelin L, Sllberg M, Lohmann V, Koh S, Bertoletti A, Chen M.J Virol. 2017 Apr 13;91(9). pii: e00010-17. doi: 10.1128/JVI.00010-17.

Cover 10

An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers.

Wijaya L, Tham CYL, Chan YFZ, Wong AWL, Li LT, Wang LF, Bertoletti A, Low JG.Vaccine. 2017 Feb 22;35(8):1175-1183. doi: 10.1016/j.vaccine.2016.12.031.

Cover 1

HBV in 2016: Global and immunotherapic insights into hepatitis B.

Mala K Maini & Antonio Bertoletti. Nature Reviews Gastroenterology & Hepatology (2017) doi:10.1038/nrgastro.2016.196

Cover 1

A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures.

Wong MT, Ong DE, Lim FS, Teng KW, McGovern N, Narayanan S, Ho WQ, Cerny D, Tan HK, Anicete R, Tan BK, Lim TK, Chan CY, Cheow PC, Lee SY, Takano A, Tan EH, Tam JK, Tan EY, Chan JK, Fink K, Bertoletti A, Ginhoux F, Curotto de Lafaille MA, Newell EW. Immunity 2016 Aug 16;45(2):442-56. doi: 10.1016/j.immuni.2016.07.007. Epub 2016 Aug 9.

Cover 1

HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant.

Mason WS, Gill US, Litwin S, Zhou Y, Peri S, Pop O, Hong ML, Naik S, Quaglia A, Bertoletti A, Kennedy PT. Gastroenterology. 2016 Jul; 151(5):986-998.e4. doi: 10.1053/j.gastro.2016.07.012. Epub 2016 Jul 22

Cover 1

Redirecting T Cell Specificity Using T Cell Receptor Messenger RNA Electroporation.

Koh S., Shimasaki N., Bertoletti A., 2016. In: Rhoads, Robert E. (Ed.), Methods in Molecular Biology 2016; 1428:285-96 Synthetic mRNA. doi: 10.1007/978-1-4939-3625-0_19.

Cover 2 Adaptive Immunity

Adaptive Immunity in HBV Infection.

Bertoletti A, Ferrari C. J Hepatol. 2016 Apr; 64(1 Suppl):S71-83. doi: 10.1016/j.jhep.2016.01.026.

Cover 3 Vaccine

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection.

Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A, Tan YJ., 2016. Vaccine. 2016 Apr 12;34(17):2008-14. doi: 10.1016/j.vaccine.2016.02.063. Epub 2016 Mar 5.

Cover 4 Drug Discovery today

Microfluidic models for adoptive cell-mediated cancer immunotherapies.

Adriani G, Pavesi A, Tan AT, Bertoletti A, Thiery JP, Kamm RD. Drug Discov Today. 2016 May 13. pii: S1359-6446(16)30156-8. doi: 10.1016/j.drudis.2016.05.006

Cover 5 J Hepatol T cell Fitness

T cell fitness in the liver: How can T cells keep it up?

Bertoletti A. 2016. J Hepatol. 2016 Jun;64(6):1208-10. doi: 10.1016/j.jhep.2016.02.035. Epub 2016 Mar 2.


Immune Response in Hepatitis B Virus Infection.

Tan A, Koh S, Bertoletti A. Cold Spring Harb Perspect Med. 2015 Aug;5(8). pii: a021428. doi: 10.1101/cshperspect.a021428.


CD161intCD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut.

Fergusson JR, Hühn MH, Swadling L, Walker LJ, Kurioka A, Llibre A, Bertoletti A, Holländer G, Newell EW, Davis MM, Sverremark-Ekström E, Powrie F, Capone S, Folgori A, Barnes E, Willberg CB, Ussher JE, Klenerman P. Mucosal Immunol. 2015 Jul 29. doi: 10.1038/mi.2015.69.


Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells.

Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, Schurich A, Singh KP, Thomas N, Das A, Chen A, Fusai G, Bertoletti A, Cantrell DA, Kennedy PT, Davies NA, Haniffa M, Maini MK. Nat Med. 2015 Jun;21(6):591-600. doi: 10.1038/nm.3856.


Overview of the special issue on HBV immunity.

Bertoletti A, Wang FS. Cell Mol Immunol. 2015 May;12(3):253-4. doi: 10.1038/cmi.2015.24.


Trained immunity in newborn infants of HBV-infected mothers.

Hong M, SandalovaE, Low D, GehringA, FieniS, AmadeiB, S.Urbani, Chong YS, GuccioneE., Bertoletti A. Nat Commun. 2015 Mar 25;6:6588. doi: 10.1038/ncomms7588.


T cell receptor-therapy in HBV-related hepatocellularcarcinoma.

Bertoletti A, Brunetto M, Maini MK, Bonino F, Qasim W, Stauss H. Oncoimmunology. 2015 Mar 19;4(6):e1008354.


Virus-specific T lymphocytes home to the skin during natural dengue infection.

Rivino L, Kumaran EA, Thein TL, Too CT, Hao Gan VC, Hanson BJ, Wilder-Smith A, Bertoletti A, J Gascoigne NR, Lye DC, Leo YS, Akbar AN, Kemeny DM, MacAry PA2. Sci Transl Med. 2015 11;7 (278) : 278ra35. doi: 10.1126/scitranslmed.aaa0526


Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells targeting HBsAg in a liver transplant patient.

Qasim W, Brunetto M, Gehring A, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini M, Bonino F, Stauss H, Bertoletti A.J Hepatol. 2015 62:468-91.


Hepatitis B: future curative strategies.

Bertoletti A, Rivino L Current Opinion in Infectious Diseases.2014 Curr Opin Infect Dis. 2014 Dec;27(6):528-34


Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Rehermann B, Bertoletti A. Hepatology. 2014 Jul 21. doi: 10.1002/hep.2732.


A whole recombinant yeast-based therapeutic vaccine elicits HBV x, s and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.

King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian M, Mc Hutchinson G,Shrivastava S, Lee Yu-Jin,Kottilil S, Bellgrau D, Rodell T, Apelian D . 2014. PLoS ONE.; 2014;9 (7):e101904.


The immune tolerant phase of chronic HBV infection: new perspectives on an old concept.

Bertoletti A, P T Kennedy Cellular & Molecular Immunology 2014. cmi201479.3d.


TLR8 agonist and bacteria trigger a potent activation of innate immune cells resident in human liver.

Jo J, Sandalova E, Ussher JE, Tang XZ,Tan AT, Natalie To, Hong , Chia A, Gill US, Kennedy PT, Tan KC, Lee KH, De Libero G, Gehring AJ, Willberg CB, Klenerman P, Bertoletti A. Plos Pathogens 2014, June 26;10(6):e1004210.


Host factor-targeted hepatitis B virus therapies.

Gehring A, Bertoletti A, Tavis JE. Intervirology. Karger Publishers; 2014;57 (3-4):158–62.


Parallel T-cell cloning and deep sequencing of human MAIT cells reveal stable oligoclonal TCRβ repertoire.

Lepore M, Kalinichenko A, Colone A, Paleja B, Singhal A, Tschumi A, Lee B, Poidinger M, Zolezzi F, Quagliata L, Sander P, Newell E, Bertoletti A, Terracciano L, De Libero G & Mori L Nature Communications 2014 May 15;5: 3866 doi:10.1038/ncomms4866.


Age-Dependent Immune Events during HBV Infection from Birth to Adulthood: An Alternative Interpretation.

Bertoletti A, Hong M.
Front Immunol. Frontiers; 2014;5:441


Building and Optimizing a Virus-specific T Cell Receptor Library for Targeted Immunotherapy in Viral Infections.

Banu N, Chia A, Ho ZZ, Garcia AT, Paravasivam K, Grotenbreg GM, Bertoletti A, Gehring A. Sci Rep. 2014 Feb 25;4.


Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner

Fletcher NF, Sutaria R, Jo J, Barnes A, Blahova M, Meredith LW, Cosset FL, Curbishley SM, Adams DH, Bertoletti A, McKeating JA. Hepatology. 2014 Apr;59(4):1320-30. doi: 10.1002/hep.26911.


Immunoprevalence and immunodominance of HLA-Cw0801 restricted T cell response targeting the HBV envelope transmembrane region.

Tan AT, Sodsai P, A, Moreau E, Chng MHY, Tham C, Zhong H, Banu N, Hirankarn, N , Bertoletti A J. of Virology 2014:88, 1332-41.


Murine models and human studies of pathogenesis of chronic hepatitis

Jo J., Tan A.T., Bertoletti A., 2014.
B. In: Thomas, H.C., Lok, A.S.F., Locarnini, S.A.(Eds.), Viral Hepatitis, Fourth ed. Chichester, West Sussex : John Wiley and Sons, Ltd, UK. pp. 176 to 187.


Immune Therapeutic Strategies in Chronic Hepatitis B Virus Infection: Virus or Inflammation Control?

Bertoletti A, Gehring AJ. 2013 Plos Pathogens: Dec9 (12): e1003784.


Defining CD8 T cell determinants during Human Viral Infection in population of Asian Ethnicity.

Rivino L, Tan AT, Chia A, Kumaran EA, Grotenbreg GM, Macary PA, Bertoletti A. J Immunol. 2013, 191: 4010-19.


Reduction of HBV replication prolongs the early immunological response to IFN-alpha therapy.

Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, Bitter H, Chu T, Gruenbaum L, Ravindran P, Zhong H, Gane E, Lim SG, Chow WC, Chen PJ, Petric R, Hibberd ML*. Bertoletti A* J Hepatol. 2013. doi:pii: S0168-8278(13)00615-6. 10.


Differential Targeting of Viral Components by CD4+ versus CD8+ T Lymphocytes in Dengue Virus Infection.

Rivino L, Kumaran EA, Jovanovic V, Nadua K, Teo EW, Pang SW, Teo GH, Gan VC, Lye DC, Leo YS, Hanson BJ, Smith KG, Bertoletti A, Kemeny DM, Macary PA. J Virol. 2013 ; 87(5):2693-706.


IL-7 Licenses Activation of Human Liver Intrasinusoidal Mucosal-Associated Invariant T Cells.

Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, Lee KH, Gehring AJ, De Libero G, Bertoletti A. J Immunol. 2013 vol. 190 (7) pp. 3142-52.


IL-1β Production through the NLRP3 Inflammasome by Hepatic Macrophages Links Hepatitis C Virus Infection with Liver Inflammation and Disease.

Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M Jr.PLoS Pathog. 2013 Apr; 9(4):e1003330.


A practical approach to immunotherapy of Hepatocellular carcinoma using T cells redirected against hepatitis B virus.

S. Koh, N Shimasaki, R Suwanarsuk, Z Z Ho, A Chia, A Gehring, H Stauss, L Renia, M Sällberg, D Campana and A Bertoletti. Molecular Therapy-Nucleic acids (2013) doi: 10.1038/mtna.2013.43.


Mobilizing Monocytes to Cross-present Circulating Viral Antigen in Chronic Infection

AJ Gehring, M Haniffa, P Kennedy, Z Z Ho, C Boni, A Shin, N Banu, SG Lim, A Chia, C Ferrari, F Ginhoux, A Bertoletti. J Clin Invest. 2013 Sep 3; 123 (9):3766-76.


Targeted Delivery of Inteferon- α To HBV-Infected Cells Using T Cell Receptor-Like Antibodies.

C Ji, KSR Sastry, G Tiefenthaler, J Cano, T Tang, ZZ Ho, D.Teoh, S. Bohini, A. Chen, S. Sankuratri, PA Macary, P.Kennedy, H Ma, S Ries, K. Klumpp, E. Kopetzki, A. Bertoletti. Hepatology 2012: 56: 2027-38


Conditional ligands for Asian HLA variants facilitate the definition of CD8 (+) T-cell responses in acute and chronic viral diseases.

Chang CX, Tan AT, Or MY, Toh KY, Lim PY, Chia AS, Froesig TM, Nadua KD, Oh HL, Leong HN, Hadrup SR, Gehring AJ, Tan YJ, Bertoletti A, Grotenbreg GM. Eur J Immunol. 2012 Dec 26. doi: 10.1002/eji.201243088.


Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells.

Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, Wasan PS, Wang XN, Malinarich F, Malleret B, Larbi A, Tan P, Zhao H, Poidinger M, Pagan S, Cookson S, Dickinson R, Dimmick I, Jarrett RF, Renia L, Tam J, Song C, Connolly J, Chan JK, Gehring A, Bertoletti A, Collin M, Ginhoux F. Immunity. 2012 ; 37(1):60-73.


Binding of TCR Multimers and a TCR-Like Antibody with Distinct Fine-Specificities Is Dependent on the Surface Density of HLA Complexes.

J L. Low, A Naidoo, G Yeo, AJ. Gehring, Z Z Ho, Y Hoe Yau,SG. Shochat, DM. Kranz, A Bertoletti, G M. Grotenbreg. PloS One. 2012 Dec 10;7(12)


TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M. J Immunol. 2012 Nov 1; 189 (9):4510-9.


Preserved T cell function in children and young adults with immune tolerant chronic hepatitis B.

P. Kennedy, E. Sandaolva, T. Tan, J. Jo, G. Foster and A. Bertoletti. Gastroenterology 2012:143 :637-645


Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection.

Bertoletti A, Ferrari C Gut. 2012 Dec; 61(12):1754–64.

Invention Filing Date Provisional / Full
Hepatitis  B virus specific antibody and uses thereof 21-Jun-10 201004457-6
HBV Epitope Reactive Exogenous T Cell Receptor (TCR) and Uses Thereof 24-Mar-11 US 201100070208 A1